SCHEMBL16633172

SCHEMBL16633172

CC(C)(C)N(C(=O)O)C(CC#N)c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
KCNH2 Q12809 1/20 0.36
SCN9A Q15858 1/20 0.36
MMP2 P08253 2/20 0.36
MMP9 P14780 2/20 0.36
EPHX1 P07099 2/20 0.36
SERPINE1 P05121 1/20 0.36
ACACB O00763 1/20 0.35
EPHX2 P34913 2/20 0.35
NR1H4 Q96RI1 1/20 0.34
GRIK1 P39086 1/20 0.34
GRIK2 Q13002 1/20 0.34
KEAP1 Q14145 1/20 0.34
NFE2L2 Q16236 1/20 0.34
PDE2A O00408 1/20 0.34
POLB P06746 1/20 0.34
TRPV1 Q8NER1 1/20 0.34
TP53 P04637 1/20 0.34
HPGD P15428 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16633980 0.85 ALDH1A1 (0.41) ALDH1A1MMP2MMP9EPHX1SERPINE1
SCHEMBL16633441 0.84 PDE2A (0.47) EPHX2PDE2A
SCHEMBL16634078 0.84 EPHX1 (0.40) ALDH1A1MMP2MMP9EPHX1SERPINE1
SCHEMBL16633204 0.82 MMP2 (0.40) ALDH1A1MMP2MMP9EPHX1SERPINE1
SCHEMBL16632995 0.81 EPHX1 (0.41) ALDH1A1MMP2MMP9EPHX1SERPINE1
SCHEMBL16633417 0.81 ALDH1A1 (0.38) ALDH1A1EPHX1SERPINE1ACACBEPHX2
SCHEMBL16633307 0.81 ALDH1A1 (0.38) ALDH1A1MMP2MMP9EPHX1SERPINE1
SCHEMBL16633428 0.81 ALDH1A1 (0.38) ALDH1A1MMP2MMP9EPHX1SERPINE1
SCHEMBL16633119 0.78 SLC6A4 (0.47) EPHX2
SCHEMBL16563726 0.76 TRPV1 (0.40) ALDH1A1EPHX1SERPINE1EPHX2NR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9469637-B2 Nitrogenated heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-10-18 US disclosed
US-20150105373-A1 NITROGENATED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105373-A1 NITROGENATED HETEROCYCLIC COMPOUND PDE2A, PDE5A, PDE3A ALDH1A1 492/4885KCNH2 869/4885SCN9A 145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.